• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthBrainstorm Health

Brainstorm Health: Canned Cranberry, Takeda Depression App, Economic Cost of Opioid Crisis

By
Clifton Leaf
Down Arrow Button Icon
By
Clifton Leaf
Down Arrow Button Icon
November 22, 2017, 1:29 PM ET

Thanksgiving dinner hosts around this great nation will have one command this year to their guests: “No politics…please.” They will hope and implore that the conversation turns to holiday plans and travel, to new babies and weddings in the extended family, school musicals, college and career ambitions, and that “cooked to perfection” turkey, for heaven’s sake—not the tax bill or tweet du jour.

I get it. And I’m damn sorry—because I have to inject a note of dissension into the holiday meal. I want to speak truth to power today and share with you what has been grating on me for years: On the grand holiday table, so-called “real” cranberry sauce is forcefully, and recklessly, displacing the canned cranberry sauce that I love. The crimson jelly roll that many of us grew up with—that jiggly, wiggly mold of tartness—is being uprooted from its rightful place on the Thanksgiving table. And in its stead, on that china-closet serving dish, is something unholy and natural, an interloper, a beguiler: something with pungent berries in it.

The move is part of the sweeping trend that is shaking the center aisles of the supermarket, as my esteemed colleague Beth Kowitt has written about so thoughtfully in the pages of Fortune: a migration away from processed foods to those that are simpler and less removed from nature. (See, for example, her magisterial 2015 cover story, “The War on Big Food.”) But the systemic deracination of the canned red barrel by the homemade berry concoction is a bridge too far.

Yes, I write about human health in this column. And yes, the shimmery, glimmery cranberry sauce I crave each November for precisely two meals a year—Thanksgiving dinner and the ritual post-Thanksgiving 10 p.m. white bread-turkey-cranberry sandwich—is composed of things that are almost surely antithetical to human health: Two of the four ingredients on most of the cans I’ve seen are high-fructose corn syrup and (plain old standard) corn syrup. But there’s an argument to be made that one amazing late-night sandwich is worth a little modest gut pollution. It’s a bonding experience for family, after all—and one likely to involve not a scintilla of political discussion. (Unless someone starts trash-talking mayo again….)

And please, dear Thanksgiving hosts, don’t sub in the organic jellied sauce for the authentic fake one. In our Fortune taste test, the verdict was unanimous that the “wholesome” organic version was unpalatable. One Fortune tester suggested it was a cross between apple sauce and cat food.

The hands-down winner of our informal office sampling—OceanSpray Jellied Cranberry Sauce (with 24 grams of sugar per serving)—went down easy, like a slippery jam, potent with berry flavor and a whiff of history. As one tester put it: “That’s the taste I grew up with, that I’ve had every Thanksgiving since I was five years old.”

And that, my friends, is the point.

Have a very happy Thanksgiving, everyone. We’ll be back here on Monday.

Clifton Leaf, Editor in Chief, FORTUNE
@CliftonLeaf
clifton.leaf@fortune.com

DIGITAL HEALTH

Takeda's depression app shows promise in trial. Drug maker Takeda and U.K.-based partner Cognition Kit have shown promising (but preliminary) results in a study of their co-developed depression app. Currently known as MDD-5003, the app is meant to help monitor people with major depression through cognitive tests that record reaction time, memory, and other metrics which paint a picture of broader mental health. The program works on the Apple Watch.(pharmaphorum)

INDICATIONS

Glaxo scores milestone 2-drug HIV cocktail approval. British drug giant GlaxoSmithKline won a critical Food and Drug Administration (FDA) approval for its landmark HIV treatment Juluca—the first HIV drug cocktail to contain just two medicines rather than three or more. HIV medicine development has transformed over the years to center on the number of therapies needed in a complete regimen; the fewer drugs involved, the lower the chance of toxic side effects. Juluca's approval could give Glaxo a leg up over its biggest competitors in the space, including U.S. biotech Gilead.(FiercePharma)

THE BIG PICTURE

The (economic) cost of the opioid epidemic: $504 billion. By now, the tragic human toll of the opioid addiction and overdose crisis has been well established. But there's a steep economic cost to the epidemic, too. And White House economists say that cost exceeded $500 billion in 2015, or nearly 3% of GDP that year.(Reuters)

REQUIRED READING

How Eliminating Net Neutrality Will Change Your Experience on the Internet, by Grace Donnelly

HPE CEO Meg Whitman Reveals Why She's Stepping Down, by Jonathan Vanian

Uber Is Already Getting Sued Over Its Gigantic Data Breach, by David Meyer

These Are the Worst Black Friday Deals, by Chris Morris

Produced by Sy Mukherjee
@the_sy_guy
sayak.mukherjee@fortune.com

Find past coverage. Sign up for other Fortunenewsletters.
About the Author
By Clifton Leaf
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

Latest in Health

FDA
HealthDrugs
Female libido pill gets expanded approval for menopause by FDA
By Matthew Perrone and The Associated PressDecember 15, 2025
14 hours ago
HealthCommentary
Nicotine pouches offer huge promise—so long as the U.S. doesn’t repeat its mistake with vaping
By Max CunninghamDecember 14, 2025
2 days ago
Thompson
C-SuiteMedia
Atlantic CEO Nick Thompson on how he learned to ‘just keep moving forward’ after his famous firing at 22
By Nick LichtenbergDecember 14, 2025
2 days ago
HealthAffordable Care Act (ACA)
A Wisconsin couple was paying $2 a month for an ACA health plan. But as subsidies expire, it’s soaring to $1,600, forcing them to downgrade
By Ali Swenson and The Associated PressDecember 13, 2025
3 days ago
Julian Braithwaite is the Director General of the International Alliance for Responsible Drinking
CommentaryProductivity
Gen Z is drinking 20% less than Millennials. Productivity is rising. Coincidence? Not quite
By Julian BraithwaiteDecember 13, 2025
3 days ago
Nicholas Thompson
C-SuiteBook Excerpt
I took over one of the most prestigious media firms while training for an ultramarathon. Here’s what I learned becoming CEO of The Atlantic
By Nicholas ThompsonDecember 13, 2025
3 days ago

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.


Most Popular

placeholder alt text
Success
'I had to take 60 meetings': Jeff Bezos says 'the hardest thing I've ever done' was raising the first million dollars of seed capital for Amazon
By Dave SmithDecember 15, 2025
20 hours ago
placeholder alt text
Success
Meetings are not work, says Southwest Airlines CEO—and he’s taking action, by blocking his calendar every afternoon from Wednesday to Friday 
By Preston ForeDecember 15, 2025
22 hours ago
placeholder alt text
Success
Sorry, six-figure earners: Elon Musk says that money will 'disappear' in the future as AI makes work (and salaries) irrelevant
By Orianna Rosa RoyleDecember 15, 2025
24 hours ago
placeholder alt text
AI
Deloitte's CTO on a stunning AI transformation stat: Companies are spending 93% on tech and only 7% on people
By Nick LichtenbergDecember 15, 2025
1 day ago
placeholder alt text
Personal Finance
Current price of silver as of Monday, December 15, 2025
By Joseph HostetlerDecember 15, 2025
24 hours ago
placeholder alt text
North America
Ford writes down $19.5 billion as it pivots electric Lighting line of vehicles
By Sasha RogelbergDecember 15, 2025
16 hours ago